https://www.mountsinai.org/care/dermatology

Mount Sinai Dermatology, 5 E 98th Street, 5th Floor, New York, NY (2025)

08/22/2025

Patients with chronic skin diseases often face significant mental health challenges, yet dermatologists may be the first, and sometimes only, clinicians to hear about symptoms like depression, anxiety, or social isolation. In a recent JAAD Ethics Journal Club piece, Dr Nicholas Gulati and colleagues from the Kimberly and Eric J. Waldman Department of Dermatology at The Mount Sinai Hospital explore the ethical and clinical complexities of psychodermatology. Should dermatologists, given their longitudinal patient relationships and broad medical training, initiate treatments such as SSRIs when psychiatric care is inaccessible? 💊

📚https://bit.ly/45XTjpp

The authors weigh beneficence - intervening to improve patient outcomes - against nonmaleficence, the duty to avoid harm, emphasizing the nuanced knowledge needed for psychotropic prescribing. While some argue for early intervention by dermatologists in select cases, others stress the importance of timely referral to mental health professionals. Proposed solutions include embedding psychiatric services in dermatology clinics, expanding telepsychiatry, and integrating formal psychiatric screening and communication training into dermatology residency. This work highlights the blurred boundaries between skin and psyche and the need for innovative models to address both simultaneously, ensuring patients receive holistic, ethically sound care.

Icahn School of Medicine at Mount Sinai

08/20/2025

A new publication on the cutting edge of AI assisted tools and how they can improve quality and efficiency at the bedside, by Dr. Jesse Lewin and colleagues 🩺💻

As artificial intelligence becomes increasingly integrated into healthcare, this study investigates the accuracy of two leading AI models—ChatGPT and Gemini—in generating CPT codes for dermatologic surgery. Accurate coding is essential for reimbursement, compliance, and workflow efficiency, especially for complex procedures like Mohs surgery, excisions, and repairs.

📚https://bit.ly/3HfCYnk

Using 90 real-world clinical cases, the authors compared AI-generated CPT codes to those assigned by a board-certified Mohs surgeon. Gemini demonstrated superior overall performance, correctly coding 91.1% of cases, compared to ChatGPT’s 74.4%. The most significant discrepancy was seen in complex repairs, where Gemini achieved 100% accuracy versus ChatGPT’s 67%. Notable errors in ChatGPT’s output included underbilling, incorrect anatomical associations, and missing modifiers—highlighting the current limitations of AI tools in clinical billing tasks.

Despite these limitations, both models show potential to support dermatologic workflows by reducing administrative burden and enhancing efficiency. Importantly, this study reflects real-time clinician usage with no prompt optimization or external resources, suggesting that performance may improve with more tailored implementations. As these technologies evolve, they may be leveraged to audit clinical documentation and ensure coding completeness, with implications for both private practice and academic dermatology.

This work underscores the importance of critical oversight when integrating AI into billing processes. AI may assist—but not yet replace—the expertise of trained dermatologic surgeons in coding accuracy and reimbursement outcomes.

Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

08/18/2025

Dr. Banu Farabi recently joined pickleball players at Wollman Rink to share her top tips for staying and playing safe in the sun: Broad-Spectrum, Water-Resistant Sunscreen (SPF 30+); UPF Clothing & UV Blocking Sunglasses; Protective Hat; & don’t forget the SPF 30 lip balm. The Mount Sinai Hospital Icahn School of Medicine at Mount Sinai

08/15/2025

From Emma Guttman, MD, PhD, and Helen He, MD, and colleagues, this new study highlights how noninvasive tape strips can reliably monitor treatment response in atopic dermatitis. By capturing gene expression from the skin surface, tape strips mirrored lesional biopsy findings after dupilumab therapy – offering a less invasive, scalable approach for clinical trials and future practice. 🧬🩹📈

📚 https://bit.ly/tapestripsBJD

We’re fortunate to have such incredible collaborative work across our Icahn School of Medicine at Mount Sinai community – where colleagues across all stages of their multidisciplinary careers unite to bring translational findings to the bedside. This publication reflects contributions from Daniel Liu and Dev Patel (medical students), Benjamin D. Hu (researcher), Arnav Mishra (data manager), Megan Lau (clinical research fellow), and Kristina Navrazhina, MD, PhD (dermatology resident). 👩‍⚕️🧑‍🔬🤝

Tape strip analysis revealed significant reductions in Th2-related genes (e.g., IL4R, CCL17, CCL22) and normalization of barrier genes (FLG, LOR) following 16 weeks of dupilumab, consistent with clinical improvement. These shifts strongly correlated with changes in matched lesional biopsies, supporting the use of tape strips as a proxy for deeper tissue sampling – especially in pediatric or longitudinal settings where invasiveness is a barrier. 🔬💡

This work advances patient-centered innovation in dermatology, making it easier to track disease activity and treatment efficacy with precision and minimal discomfort.

The Mount Sinai Hospital

08/13/2025

Our Annual Report outlines our many achievements in 2024. We delivered comprehensive and superior dermatological care with more than 118,000 patient visits and conducted groundbreaking, translational research.
With a record number of publications and patent applications, our efforts continue to position the Department at the world’s epicenter of research in inflammatory diseases, such as eczema/atopic dermatitis, alopecia areata, scarring alopecia, psoriasis, vitiligo, hidradenitis suppurativa, and keloids, as well as skin cancers and other skin diseases.
Details: https://reports.mountsinai.org/report/derm2025
The Mount Sinai Hospital Icahn School of Medicine at Mount Sinai

08/11/2025

By Dr. Andrew Ji and colleagues, this new study explores racial disparities in post-transplant skin cancer—specifically basal cell and squamous cell carcinomas—in a cohort of over 10,000 solid organ transplant recipients from the Mount Sinai Health System. While white patients had a significantly higher incidence of keratinocyte carcinoma, time to diagnosis was similar across racial groups. 🧑‍⚕️🧬📊

📚https://bit.ly/4o4UjQJ

This is a crucial insight for dermatologic and transplant care. Historically, white race has been associated with higher skin cancer risk post-transplant, but this study emphasizes that non-white patients—while at lower risk overall—develop these cancers within the same time window. Early and equitable screening for all SOTRs remains essential. 🕒🔎📅

We're proud that this work comes from our Icahn School of Medicine at Mount Sinai community—where rigorous, data-driven research is advancing equitable care. Studies like this one reaffirm the importance of precision dermatology and challenge assumptions in clinical algorithms. ✍️📈🏥

The Mount Sinai Hospital

08/08/2025

Selective IL-13 inhibition is redefining the systemic treatment landscape for moderate-to-severe atopic dermatitis. In this multicenter study led in part by Emma Guttman-Yassky, MD, PhD, lebrikizumab—an IL-13 monoclonal antibody—demonstrated rapid and sustained reductions in key type 2 inflammatory biomarkers with strong clinical correlations across EASI, IGA, and pruritus scores. 💉🔬

📚https://bit.ly/4lSpH3s

Patients with AD in the ADvocate1 and ADvocate2 trials showed significantly elevated serum IL-13, CCL13, CCL17, CCL22, periostin, and IgE at baseline compared to healthy controls. By week 4, lebrikizumab treatment led to downregulation of these biomarkers, with normalization sustained through week 52. Particularly notable was the identification of CCL26 as a pharmacodynamic marker for response, underscoring its potential utility in therapeutic monitoring. 🧬📉

Clinical improvement mirrored molecular changes: the greater the suppression of CCL17, CCL22, CCL26, periostin, and CCL13, the more robust the improvements in disease severity and itch. Serum biomarkers aligned closely with lesional skin transcriptomics, reinforcing their value as systemic indicators of disease activity and response. 🧪📊

This translational work highlights IL-13—not IL-4—as the dominant cytokine in AD pathogenesis, supporting IL-13–targeted therapy as a core strategy in long-term disease control. Lebrikizumab’s ability to reduce inflammatory burden without broad immunosuppression signals a promising step forward in precision dermatology. ✨🧴

08/08/2025

Congratulations to our C2C STAR Raffle Winners! 👏
April Hussain ☀️
Patricia Toro ☀️
Zoan Powell-Brown ☀️
🎉 👏Congratulations to the recipients and thank you to everyone who took time to recognize their colleagues!
🙌Use STAR to say thank you to your colleagues!!
The Mount Sinai Hospital

08/07/2025

Congratulations! We are grateful for
Avril Reivers 🌟
Robert Lopez 🌟
for celebrating 10 years with Mount Sinai. 👏 🙌
We're truly inspired by their amazing dedication and deeply appreciate the positive impact they make every single day.
The Mount Sinai Hospital

08/06/2025

Published in part by Brian S. Kim, MD, MTR - one of our esteemed faculty at Icahn School of Medicine at Mount Sinai - this global consensus redefines how we understand and treat pruritus. The updated definition, shaped by a multidisciplinary Delphi process including patients, clinicians, and researchers, recognizes pruritus not merely as a symptom but as a disease entity with distinct acute and chronic forms. Chronic pruritus is now defined by a duration of more than 6 weeks, with complex internal and external drivers and major impact on quality of life. ✍️🧠🌍

📚https://bit.ly/4lNreHK

This unified framework reflects our growing understanding of itch as a neurobiologic disorder, on par with chronic pain, deserving of targeted therapies and formal clinical recognition. The new definition aims to standardize terminology across research, clinical trials, and regulatory pathways, ensuring patients worldwide receive more accurate diagnoses and access to appropriate treatment. 🚑💬🔬

With this international effort, itch is no longer just an associated complaint, rather an independent, complex sensory condition that calls for focused, collaborative management.

The Mount Sinai Hospital

08/04/2025

Dr. Emma Guttman presented a synopsis of her recently published paper in Allergy, European Journal of Allergy and Clinical Immunology (EAACI)—“Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy”.
View the video: https://www.youtube.com/watch?v=5bFWTd3V5bM
Read the publication: https://onlinelibrary.wiley.com/doi/10.1111/all.16659

08/01/2025

A new clinical letter in Pediatric Dermatology presents a compelling case of localized morphea successfully treated with topical ruxolitinib 1.5% cream in a 17-year-old patient — offering a promising non-systemic therapeutic option for superficial fibrosing dermatoses. ✨🧴

This case, authored in part by Dr. Grace Rabinowitz — a recent Icahn School of Medicine at Mount Sinai MD/MSCR graduate — alongside Nicholas Gulati, MD, PhD, Saakshi Khattri, MD, and Justine Fenner, MD, describes a plaque that initially worsened despite clobetasol treatment, then stabilized and ultimately improved with targeted therapy. The patient’s lesion progressed from a hypopigmented plaque with erythematous border at presentation (a), to enlargement after 4 weeks of clobetasol 0.05% ointment twice daily (b). Following one intralesional triamcinolone injection and initiation of ruxolitinib cream twice daily, significant clinical improvement was observed after 4 months (c), with near-complete resolution and residual hyperpigmentation after 11 months (d). 👩‍⚕️🧒

📚https://bit.ly/45a26UH

Mechanistically, this aligns with recent data showing an interferon-γ signature in morphea fibroblasts, implicating the JAK/STAT pathway in its pathogenesis. As a JAK1/2 inhibitor, topical ruxolitinib—currently approved for atopic dermatitis and vitiligo in patients ≥12 years—may modulate this inflammatory cascade, especially during the early inflammatory phase of disease. The superficial distribution of fibrosis in this case supported the decision to use topical therapy over systemic agents. 🧬💡

With limited literature guiding the management of recalcitrant localized morphea, this case contributes important evidence toward expanding the therapeutic role of topical JAK inhibitors. It also reinforces the potential of early immunologically-informed interventions to minimize long-term cutaneous damage and improve pediatric outcomes. 🩺📈

The Mount Sinai Hospital

Mount Sinai Dermatology

08/22/2025

08/20/2025

08/18/2025

08/15/2025

08/13/2025

08/11/2025

08/08/2025

08/08/2025

08/07/2025

08/06/2025

08/04/2025

08/01/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Featured

Share

Category